Download MendeleyA Numb-Mdm2 fuzzy complex reveals an isoform-specific involvement of Numb in breast cancer.
Colaluca, I.N., Basile, A., Freiburger, L., D'Uva, V., Disalvatore, D., Vecchi, M., Confalonieri, S., Tosoni, D., Cecatiello, V., Malabarba, M.G., Yang, C.J., Kainosho, M., Sattler, M., Mapelli, M., Pece, S., Di Fiore, P.P.(2018) J Cell Biol 217: 745-762
- PubMed: 29269425
- DOI: https://doi.org/10.1083/jcb.201709092
- Primary Citation of Related Structures:
5NJJ, 5NJK - PubMed Abstract:
Numb functions as an oncosuppressor by inhibiting Notch signaling and stabilizing p53. This latter effect depends on the interaction of Numb with Mdm2, the E3 ligase that ubiquitinates p53 and commits it to degradation. In breast cancer (BC), loss of Numb results in a reduction of p53-mediated responses including sensitivity to genotoxic drugs and maintenance of homeostasis in the stem cell compartment. In this study, we show that the Numb-Mdm2 interaction represents a fuzzy complex mediated by a short Numb sequence encompassing its alternatively spliced exon 3 (Ex3), which is necessary and sufficient to inhibit Mdm2 and prevent p53 degradation. Alterations in the Numb splicing pattern are critical in BC as shown by increased chemoresistance of tumors displaying reduced levels of Ex3-containing isoforms, an effect that could be mechanistically linked to diminished p53 levels. A reduced level of Ex3-less Numb isoforms independently predicts poor outcome in BCs harboring wild-type p53. Thus, we have uncovered an important mechanism of chemoresistance and progression in p53-competent BCs.
Organizational Affiliation:
The FIRC Institute for Molecular Oncology Foundation, Milan, Italy.
